We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+17.27%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.99B
AUM Growth
+$232M
Cap. Flow
+$89.4M
Cap. Flow %
4.5%
Top 10 Hldgs %
47.8%
Holding
194
New
23
Increased
33
Reduced
38
Closed
65

Top Buys

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$46.6M
2
PBYI icon
Puma Biotechnology
PBYI
+$41M
3
DOVA
Dova Pharmaceuticals, Inc. Common Stock
DOVA
+$35.9M
4
CORI
Corium International, Inc.
CORI
+$19M
5
ISRG icon
Intuitive Surgical
ISRG
+$17.9M

Top Sells

Rank Stock Value
1
ACRS icon
Aclaris Therapeutics
ACRS
+$37.6M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$22.2M
3
NVRO
NEVRO CORP.
NVRO
+$20.4M
4
AVXS
AveXis, Inc. Common Stock
AVXS
+$13.3M
5
AMAG
AMAG Pharmaceuticals
AMAG
+$12.6M

Sector Composition

Rank Sector Weight
1 Healthcare 96.26%
2 Consumer Staples 0.19%
3 Consumer Discretionary 0.06%
4 Energy 0.04%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACHC icon
126
Acadia Healthcare
ACHC
$2.85B
– –
-1
Closed –
ACRS icon
127
Aclaris Therapeutics
ACRS
$911M
– –
-1,260,847
Closed -$37.6M
AGEN
128
Agenus
AGEN
$371M
– –
-183
Closed -$14K
AMGN icon
129
Amgen
AMGN
$238B
– –
-20,000
Closed -$3.28M
AORT icon
130
Artivion
AORT
$1.33B
– –
-123
Closed -$2K
APVO icon
131
Aptevo Therapeutics
APVO
$4.34M
– –
0
– -$1K
ARCT icon
132
Arcturus Therapeutics
ARCT
$450M
– –
-1,301
Closed -$10K
ATRC icon
133
AtriCure
ATRC
$2.45B
– –
-55
Closed -$1K
BIO icon
134
Bio-Rad Laboratories Class A
BIO
$10.4B
– –
-49,416
Closed -$9.85M
BMRN icon
135
BioMarin Pharmaceuticals
BMRN
$12.7B
– –
-250
Closed -$22K
BSX icon
136
Boston Scientific
BSX
$69.8B
– –
-3
Closed –
CAPR icon
137
Capricor Therapeutics
CAPR
$544M
– –
-400
Closed -$13K
CERS icon
138
Cerus
CERS
$552M
– –
-740
Closed -$3K
CLDX icon
139
Celldex Therapeutics
CLDX
$3.19B
– –
-465
Closed -$25K
DHR icon
140
Danaher
DHR
$151B
– –
-3
Closed –
ELV icon
141
Elevance Health
ELV
$87.3B
– –
-3,081
Closed -$510K
EVH icon
142
CALL
Evolent Health
EVH
$556M
– –
-50,000
Closed -$190K
ILMN icon
143
Illumina
ILMN
$34B
– –
-3,598
Closed -$597K
IVV icon
144
iShares Core S&P 500 ETF
IVV
$894B
– –
-1
Closed –
IWS icon
145
iShares Russell Mid-Cap Value ETF
IWS
$15.9B
– –
-2
Closed –
MASI
146
DELISTED
Masimo
MASI
– –
-5,945
Closed -$554K
MCK icon
147
McKesson
MCK
$105B
– –
-3,601
Closed -$534K
NERV icon
148
Minerva Neurosciences
NERV
$259M
– –
-101,317
Closed -$6.57M
PAHC icon
149
Phibro Animal Health
PAHC
$1.46B
– –
-18,382
Closed -$517K
HIND
150
Vyome Holdings
HIND
$15.2M
– –
0
– –
4 5
6
7 8

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Perceptive Advisors's Q2 2017 Portfolio in Review

As of Q2 2017, Perceptive Advisors held 194 positions worth $1.99B, up 13% from $1.76B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Perceptive Advisors deployed $89.4M of net new capital in Q2 2017, opening 23 new positions and adding to 33 existing holdings. Its largest new stake was Puma Biotechnology: 733,320 shares worth $64.1M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 98% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $22.2M trimmed.

  • Perceptive Advisors's largest Q2 2017 buy was Puma Biotechnology: 733,320 shares worth $64.1M.
  • Perceptive Advisors added most to Alnylam Pharmaceuticals in Q2 2017, an estimated $46.6M increase.
  • Perceptive Advisors's biggest Q2 2017 reduction was Sarepta Therapeutics, cutting an estimated $22.2M.
  • Perceptive Advisors fully exited Aclaris Therapeutics in Q2 2017, selling an estimated $37.6M.
  • Perceptive Advisors's ten largest holdings make up 48% of its $1.99B portfolio in Q2 2017.
  • Perceptive Advisors opened 23 new positions and closed 65 in Q2 2017.
  • Perceptive Advisors's portfolio value rose 13% quarter-over-quarter to $1.99B.

Based on Perceptive Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.